Close

Research Insight

Medtronic CEO and chairman Omar Ishrak to make a formal presentation on the company at CEO Investor Forum 3.0

Medtronic plc , the global leader in medical technology announced it will participate in the CECP CEO Investor Forum 3.0 in New York on Monday, February 26, 2018, at 4:00 p.m. EST. Omar Ishrak, chairman and chief executive officer of...

Medtronic’s pediatric study: Minimed(TM) 670G shows positive results among children aged 7 to 13

Medtronic plc , the global leader in medical technology announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes...

Austin Area Obstetrics, Gynecology and Fertility Completes Successful First Year of Clinical Research

Since it started offering patients the opportunity to participate in clinical research a year ago, Austin Area Obstetrics, Gynecology and Fertility has provided research opportunities to more than 100 patients, announced Jinous Rouhani, practice CEO. The top-rated obstetrics and gynecology...

Compound designed to fight Alzheimer’s disease shows promise in the lab

The year was 1906, and German physician Alois Alzheimer was examining the brain of a patient who had died after a battle with progressive dementia. The woman had experienced memory loss and other psychological changes. Alzheimer noticed the accumulation of...

Long-term protection against HIV : Gene therapy using CAR T cells

A UCLA-led research team has created blood-forming stem cells that can carry a gene that allows the body to produce cells that can detect and destroy HIV-infected cells. The blood-forming cells, called hematopoietic stem and progenitor cells, or HSPCs,...

Phase 3 PROSPER Trial Shows XTANDI Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results from the Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The results show that the use...

Leading Advances in Transplant Medicine

NYU Langone has assembled a team dedicated to cutting-edge research, to reinforce and energize the Transplant Institute’s commitment to world-class care. Dr. Kon, who comes to NYU Langone from the University of Maryland Medical Center, brings significant research experience...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read